PCSK9-Inhibitoren stehen in Deutschland seit Herbst 2015 zur Therapie von Hypercholesterinämie und gemischter Dyslipidämie zur Verfügung. Aufgrund der hohen Therapiekosten stellt sich die Frage, für welche Patienten sie in Frage kommen und wer sie verordnen darf.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Sabatine, M.S., et al., Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med, 2015. 372(16): p. 1500–9.
Robinson, J.G., et al., Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med, 2015. 372(16): p. 1489–99.
Sabatine, M.S., et al., Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017. 376(18): p. 1713–1722.
Moriarty, P.M., et al., Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J, 2016. 37(48): p. 3588–3595.
Raal, F.J., et al., Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation, 2011. 124(20): p. 2202–7.
Stein, E.A., et al., Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation, 2013. 128(19): p. 2113–20.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Busygina, K., Parhofer, K.G. Die Verordnung von PCSK9-Inhibitoren ist klar geregelt. MMW - Fortschritte der Medizin 160, 43–46 (2018). https://doi.org/10.1007/s15006-018-0091-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-018-0091-2